Fig. 5
Comparison of the efficacy of oral treatment with OM-85 on S. pneumoniae “primary infection” versus “super-infection” (i.e. post-influenza) in mice. a and c. Survival of mice treated with OM-85 or BLANC subsequently infected with S. pneumoniae at 3.5 × 107 CFU dose (Dose C). b and d Survival of mice treated with OM-85 or control solution (BLANC) and subsequently infected with sublethal dose (100 plaque forming units or PFU) of influenza virus strain PR8, and 7 days later with S. pneumoniae at 1.0 × 105 CFU dose. The percentage of mice surviving the infection is on the ordinate and the days after the infection on the abscissa. Data are representative of 3 experiments with 5–6 mice per time point